HUONS CO., LTD.

243070KOSDAQPharmaceuticals

HUONS CO., LTD. (243070, KOSDAQ) reported KRW 621bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20235525650537330Consolidated
20245904029606351Consolidated
20256214642415Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202310.1%9.1%61.5%15.2%
20246.7%4.9%57.8%8.3%
20257.3%6.8%10.2%

Revenue moved 12.5% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 249bn
Close priceKRW 20,750
Listed shares11,979,665
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)1,087
Women426 (39.2%)
Average tenure4.4 years
Annual pay, menKRW 63,751,000
Annual pay, womenKRW 49,196,000
Pay ratio, women to men77.2%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →